ONCOBREAST-TEST Is a Quick Diagnostic, Prognostic and Predictive Method of Response to Systemic Treatment

Area of Science:

• Oncology
• Medical Diagnostics
• Personalized Medicine

Background:

• Breast cancer treatment relies on chemotherapy, but predicting drug response is challenging.
• Current methods lack accuracy in determining individual tumor chemosensitivity.
• Personalized therapy aims to tailor treatments for better efficacy and reduced toxicity.

Purpose of the Study:

• To introduce ONCOBREAST-TEST, a novel diagnostic and therapeutic procedure for breast cancer.
• To assess the chemosensitivity of isolated breast cancer cells prior to chemotherapy.
• To enable personalized treatment selection for improved patient outcomes.

Main Methods:

• Utilized MTT assay, morphological assessment, LDH activity, and flow cytometry (apoptosis, proliferation, cell markers, Ki-67).
• Developed diagnostic panels for predicting tumor cell chemosensitivity.
• Integrated results for simple, minimally invasive, and quick assessment.

Main Results:

• ONCOBREAST-TEST accurately predicts chemosensitivity of breast cancer cells.
• Identified optimal therapies: docetaxel/cyclophosphamide for G3 NOS, paclitaxel +/- trastuzumab for G1 NOS.
• Demonstrated potential for personalized chemotherapy selection.

Conclusions:

• ONCOBREAST-TEST offers a simple, rapid, and accurate method for assessing breast cancer chemosensitivity.
• Enables personalized therapy selection, increasing chemotherapy effectiveness.
• Reduces side effects, protects patient health, and shortens treatment duration, yielding economic and social benefits.